The present study focused 'marijuana', 'cannabinoids', 'tetrahydrocannabinol', 'THC', 'Pediatric' 'cannabidiol', 'CBD', 'cannabidivarin', 'CBDV', 'seizures' and 'epilepsy' 
Introduction Fig 1.
Molecular structure of Medicinal THC and CBD [9, 10] 
Aim
The main objective of this review was:
a. To understand the role of medicinal cannabis in the treatment of epilepsy, b. To assess preclinical and clinical safety and efficacy of medicinal cannabis in reducing tonic seizures caused by epilepsy. c. To understand the ethical issues and considerations behind the legal use of medicinal cannabis for the treatment purposes worldwide.
Search methodology
The core text that was focused throughout the article write up was 'Epilepsy and Cannabis'. All types of studies were included as there were very few clinical trials conducted in this regard. Moreover, children, Adolescents and Adults suffering from Epileptic seizures were included in this review. The methodology being adopted for the relevant literature review, searching the databases like, PUBMED, Cochrane Library, MEDLINE, EMBASE, Clinical trials. gov by using keywords such as, 'cannabis', 'marijuana', 'cannabinoids', 'tetrahydrocannabinol', 'THC', 'cannabidiol', 'CBD', 'cannabidivarin', 'CBDV', 'seizures' and 'epilepsy' was utilized. Moreover, a greater number of google searches were done to gather reliable and valid information from websites primarily focusing on safety and efficacy of medicinal cannabis use in epileptic patients. The search was confined to studies being published in English language. Moreover, PRISMA methodology was adopted for inclusion of relevant studies. 
Ethical considerations
Medicinal Cannabis had remained lodged in Schedule I under the 1970 Controlled Substances Act of the U. S. federal Controlled Substances Act, meaning it has "no currently accepted medical use and a high potential for abuse, due to which cannabis was highly restricted and prohibited to be used for clinical research [30] . However, the extensive literature research on therapeutic cannabis had been reviewed over the past several years by various governmental and academic bodies, including the U. S. National Academy of Sciences-Institute of Medicine, UK House of Lords, and Canadian Senate Committee on Illegal Drugs which reported in the confirmation of the therapeutic value of medicinal cannabis [31] . From the above review, it could be concluded that there were some ethical issues in Clinical Practice of Medicinal Cannabis. The doctors cannot dispense the drug in any form. The doctors could recommend, however, are not allowed to prescribe medicinal cannabis [8] . The goal of palliative care, is to improve the quality of life for a patient by preventing or relieving symptoms of disease and side effects of treatments [8] . On one side, the use of medicinal cannabis contributed to the good effects it could have produced by supporting the factor of 'Beneficience' in accord of ethical conduct to practice medicine. But, on the other hand, it violated the 'Non-malfeasance'factor which was meant for doing no harm to the patient while conducting clinical trial ethically [8] . On the contrary, both the factors were found to be very contradictory and conflicting as well. The ethical question that arose was the existence of any practices that could control medicinal cannabis abuse, educational qualification for recommending medicinal therapeutic cannabis and integration of the treatment into the routine health assessment care [8] .
Discussion
From the above literature reviewed, it could be suggested that anecdotal evidence was sufficient to support the fact that some children suffering from epilepsy and seizures got benefited up to some extent by the use of oral medicinal cannabis. This further provided an evidence-based approach for proposing and determining objective data and requirement of Randomized placebo-controlled trials. From ethical point of view, seriously ill patients (Children and adults) have the right to access effective therapies that improved their quality of life, however, if this right is denied then their dignity and respect might get harmed which ultimately might force them to go out of the way to access the medical care. On the other hand, the data collected from various sources pointed in a direction that none of the medicinal cannabinoid product was tested for its safety and efficacy for long term usage in children and adults suffering from epilepsy. Moreover, only a small number of case reports and surveys existed with conflicting results that included pediatric patients with epilepsy in greater number.
Review of clinical data interpretation: It was observed that there were comparatively less number of clinical trials as compared to preclinical trials conducted in the subsequent years from 1973 to 2015. During these span of years, it was observed that Medicinal Cannabis was used as an intervention in the age group of children suffering from epilepsy in comparison to the adults and adolescents suffering from epilepsy. Moreover, it was seen that oral Medicinal Cannabis and Cannibidiol were well tolerated as compared to inhaled Medicinal Cannabis amongst epileptic patients by reduction of tonic seizures and marked improvement in the frequency and intensity of seizure control, motor skills, awareness, postural tone, speaking ability with positive psychotropic effects on the epileptic patients suffering. However, the question of use of Medicinal Cannabis for its long-term use and effects to alleviate the symptoms of epilepsy in patients is still conflicting due to lack of evidence based trials. There was only one randomized controlled study being conducted which was considered to be a pilot study with small sample size, thus inhibiting safety and efficacy of Medicinal use of Cannabis in epilepsy. On the other hand, mild adverse effects were found to be associated with the intervention of medicinal Cannabis and its derivatives, that were, namely, fatigue, developmental regression, abnormal movements, appetite reduction, diarrhea, sedation and unsteadiness [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .
Review of preclinical data interpretation: During preclinical study review, it was observed that maximum number of preclinical trials was conducted on Rat models in comparison to few numbers of preclinical trials being conducted on Chicken model and Mice model. It was also predicted that the adverse effects associated with the intervention of medicinal Cannabis in animal models showed none to minimal side-effects which led to the evidence based fact that medicinal Cannabis and its derivatives could be used safely in humans in a clinical setting. The outcomes observed from the preclinical study of medicinal cannabis intervention were reduction in EEG activity, tonic seizures, and susceptibility with low mortality rate and increased threshold which further pointed towards the fact that the medicinal cannabis drug intervention was well-tolerated in animal models [21] [22] [23] [24] [25] [26] [27] [28] [29] .
According to 'Partners Against Mortality in Epilepsy (PAME)', epilepsy affected 3 million Americans, creating a blind spot for caregivers that could prove devastating because epilepsy is often not listed as a cause of death on death certificates, making it difficult for public health officials to quantify and draw attention to the problem [32] . The lack of data also challenged to find a best alternative treatment to cure epilepsy both in children and adults. [32] .
Clinical trials pending
Following are the awaited high methodology quality Prospective data for evaluating safety and efficacy of Medicinal Cannabis for the treatment of Epilepsy in children as well as, adult population. 
Uncontrolled epileptic patients
To study the antiepileptic effect of cannabidioloil in a specific genetic epilepsy patients.
Conclusion
Further investigations are required to fill the gaps between knowledge and understanding the mechanisms of action with the use of medicinal cannabis in people with epilepsy. There is a scarcity and dearth of data and knowledge regarding the practice guidelines including patient education for medicinal cannabis use in epilepsy. Without accurate, systematic data it was very challenging to determine the safety and efficacy of medicinal cannabis in epileptic patients [32] . On the other hand, evidence from laboratory studies, anecdotal reports, and small clinical studies from a number of years ago suggested that medicinal cannabis, potentially helped in controlling seizures. However, conducting studies could be difficult as researchers have limited access to cannabis due to federal regulations, lack of scientific data on the usefulness and safety of cannabis, increased financial and time constraints [9] . The use of medicinal cannabis is an ethical issue as it possessed both good and bad results-'hindrance for getting legalized'. But, on the contrary the patient suffering has the right to access the better conventional and alternative treatment for the better qualiy of life. This factor could motivate people to black-market purchasing of medicinal cannabis. Therefore, introduction of Legislation based on internationally accepted human rights standards could prevent discrimination and rights violations, improved access to health-care services, and raise the quality of life for people with epilepsy [6] . The Food and Drug Administration is conducting a review of scientific evidence to determine whether cannabis had similar or improved effect as compared to existing treatment medications for treating epilepsy [30] . In India, the Ministry of Health and Family Welfare had proposed a National Epilepsy Program in order to, increase the public awareness about Epilepsy and fill the gap between the treatment and Quality of care in the country [7] . Thus, it could be concluded that when medicinal cannabis was used as directed in preclinical and clinical trials, the side effects were comparatively low [31] .
In a nutshell, the present study focussed on medicinal cannabis and its derivatives to be further investigated for its effectiveness in treating epilepsy so that every person would get compassionate access to the treatment giving rise to a complete revolution to treat EPILEPSY.
Future directions
There is a need for more data regarding the safety and efficacy which measured the potential benefits and risks of Medicinal Cannabis and its derivatives to be used for epileptic patients by using EEG as a biomarker. Studies need to be conducted for calculating and identifying the optimal dosing, tolerability and standardization of the medicinal cannabis preparation to be used in different population suffering from epilepsy. Further, there is an urgent need for strict guidelines and regulations for standardization of medicinal cannabis in clinical research industry. Moreover, projects at regional, national as well as, international level should be implemented to fill the gap between people with epilepsy and society by proper training and education into health systems to dispel the stigma worldwide [6] .
Limitations of the study
 Quality of the data collected and retrieved through searching was highly variable and conflicting.  Included studies showed uncertainty about the doses and quality of the product composition.  Several data were found to be missing in the included studies, like, patients' followup, number and frequency of seizure counts, length and severity of seizures.  The cost-effectiveness of the Medicinal Cannabis intervention and the travel cost tools were not included in the study.
